New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
04:55 EDTLIFE, LIFE, LIFE, SI, SI, SI, BIOL, BIOL, BIOL, IVC, IVC, IVC, VAR, VAR, VAR, ARAY, ARAY, ARAY, CPHD, CPHD, CPHD, MASI, MASI, MASI, HRC, HRC, HRC, RHHBY, RHHBY, RHHBY, MCK, MCK, MCKWorldwide Business Research to host a conference
Field Service Medical Conference is being held in San Diego on February 19-21.
News For LIFE;RHHBY;HRC;MASI;CPHD;ARAY;VAR;IVC;BIOL;SI;MCK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 23, 2015
06:37 EDTIVCInvacare reports Q2 European net sales down 16.7% to $128.2M
Reports Q2 North America/Home Medical Equipment net sales down 11.4% to $119M. Reports Q2 IPG sales up 6.1% to $27.4M. Reports Q2 Asia/Pacific sales down 9.3% to $11.7M.
06:36 EDTIVCInvacare reports Q2 adjusted EPS (23c), consensus (21c)
Subscribe for More Information
06:27 EDTRHHBYRoche CEO expects biosimilars in Europe by late 2017, Reuters reports
Subscribe for More Information
05:46 EDTRHHBYRoche expects FY15 sales to grow low- mid-single digits
Expects FY15 core EPS to grow ahead of sales at constant exchange rates. Roche expects to further increase dividend in Swiss francs.
05:45 EDTRHHBYRoche reports 1H15 core EPS CHF 7.22 vs. 7.57 last year
Subscribe for More Information
July 21, 2015
09:03 EDTMASIMasimo sees Q2 EPS 35c-36c, consensus 30c
Subscribe for More Information
08:35 EDTVARVarian Medical signs agreement to operate first proton facility in New York
Varian Medical Systems (VAR) announced that it has entered into an agreement with New York Proton Management, a consortium of leading New York healthcare institutions including Memorial Sloan Kettering Cancer Center, Mount Sinai Health System, Montefiore Health System, and ProHEALTH Medical Management formed to operate The New York Proton Center, the first proton facility in New York State. Varian will provide the center, which will have four treatment rooms and a research room, with its ProBeam system, as well as 10 years of service for approximately $115M. The center, which will be located in Manhattan, is expected to open for treatment in the first half of 2018. Varian expects to book the equipment portion of the order in Q4 with the remainder of the order to be booked in accordance with the company's policies over the term of the agreement. Under an agreement with MM Proton I, LLC, the project developer, Varian's international subsidiary in Switzerland will provide $91.5M in project financing, including a six-and-half-year $73M senior first lien loan at 9% interest and a six-and-half-year $18.5M subordinate loan at up to 13.5% interest. Other lenders for the $242.7M in total project loans include JPMorgan Chase Bank (JPM) and an affiliate of The Goldman Sachs Group (GS). The project facility is managed by Murphy & McManus, a Boston-based developer of healthcare and life science facilities and Norton Travis of NLT Advisors served as project coordinator on behalf of the consortium.
07:05 EDTRHHBYOphthotech names Shima as Chief Scientific Officer, Bjarke as CCO
Subscribe for More Information
July 20, 2015
07:33 EDTRHHBY, CPHDInternational AIDS Society to hold a conference
Subscribe for More Information
07:32 EDTLIFEaTyr Pharma announces transitions in clinical developments
Subscribe for More Information
06:17 EDTCPHDMizuho sees Q2 earnings beats in Diagnostics space
Subscribe for More Information
05:13 EDTRHHBYRoche expands HIV Global Access Program
Roche announced an expansion to the HIV Global Access Program to include early infant HIV diagnostic testing for low and middle income countries. Roche, in partnership with the Joint United Nations Programme on HIV/AIDS, or UNAIDS, the Clinton Health Access Initiative, or CHAI, UNITAID, the U.S. President's Emergency Plan For AIDS Relief, or PEPFAR, and the Global Fund to fight AIDS, TB and Malaria, is committed to working with the Diagnostics Access Initiative by providing state-of-the-art solutions to achieve the 90-90-90 goal set forth by UNAIDS. Announced in 2014, the HIV Global Access Program is Roche's most recent addition to the AmpliCare Initiative, which launched in 2002 in South Africa.
July 16, 2015
10:00 EDTMASIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:42 EDTMASIMasimo downgraded to Neutral from Buy at BTIG
Subscribe for More Information
July 15, 2015
08:07 EDTVARVarian Medical commences treatment of RapidPlan in Australia
Subscribe for More Information
July 14, 2015
09:06 EDTCPHDCepheid price target raised to $67 from $58 at Wedbush
Subscribe for More Information
08:56 EDTMCKMorgan Stanley names 'Vintage Values 2016' list
Morgan Stanley named its "Vintage Values 2016" list, comprised of the firm's analysts' best ideas to hold over the next 12 months. Included on the list are Ameriprise (AMP), Apple (AAPL), Bank of America (BAC), Comcast (CMCSA), Crown Castle (CC), Estee Lauder (EL), Hilton (HLT), Ingersoll-Rand (IR), LinkedIn (LNKD), Magna (MGA), Marathon Oil (MRO), McKesson (MCK), Oaktree Capital (OAK), Thermo Fisher (TMO) and Visa (V).
08:32 EDTHRCHill-Rom's acquisition of Welch Allyn receives FTC antitrust clearance
Hill-Rom Holdings announced that the FTC has granted early termination of the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Hill-Rom's planned acquisition of Welch Allyn Holdings. As previously announced on June 17, 2015, Hill-Rom and Welch Allyn have entered into a definitive merger agreement under which Hill-Rom will acquire Welch Allyn for approximately $2.05B in cash and stock.
07:03 EDTARAYAccuray reports studies on clinical use of CyberKnife System robotic SBRT
Subscribe for More Information
06:04 EDTRHHBYRoche says atezolizumab met primary endpoint in IMvigor 210 trial
Roche announced that in the IMvigor 210 study, the investigational cancer immunotherapy atezolizumab shrank tumors -- objective response rate, ORR, the primary end point of this Phase II study -- in people with locally advanced or metastatic urothelial bladder cancer who had progressed on initial treatment. High amounts of PD-L1 expression by a person’s cancer correlated with increased response to the medicine. Adverse events were consistent with what has been previously observed for atezolizumab. Sandra Horning, M.D., chief medical officer and head of Global Product Development, said, “We plan to present results at an upcoming medical meeting and will discuss next steps with health authorities to bring a new treatment option to patients as soon as possible.” Last year, the U.S. FDA granted Breakthrough Therapy Designation for atezolizumab in people whose metastatic bladder cancer expressed PD-L1. This designation is designed to expedite the development and review of medicines intended to treat serious diseases. In addition to the IMvigor 210 study, Roche has an ongoing randomised Phase III study, IMvigor 211, comparing atezolizumab with standard-of-care chemotherapy in people who have relapsed UBC, and a planned Phase III study, IMvigor 010, that will evaluate atezolizumab compared with observation in people with early-stage muscle-invasive bladder cancer who are selected for PD-L1 expression and are at risk for recurrence.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use